1. Cationic amphiphilic molecules as novel sclerosants for venous malformation treatment: A study on tranexamic acid-derived low-molecular-weight gels.
- Author
-
Chen Y, Song D, Hou Q, Ma M, Zhao X, Yang T, Xie H, and Ding P
- Subjects
- Animals, Molecular Weight, Sclerosing Solutions therapeutic use, Sclerosing Solutions chemistry, Gels chemistry, Humans, Cations chemistry, Surface-Active Agents chemistry, Surface-Active Agents pharmacology, Surface-Active Agents therapeutic use, Veins drug effects, Veins abnormalities, Male, Mice, Fatty Alcohols chemistry, Fatty Alcohols pharmacology, Fatty Alcohols therapeutic use, Tranexamic Acid therapeutic use, Tranexamic Acid pharmacology, Sclerotherapy methods, Vascular Malformations drug therapy, Vascular Malformations therapy, Vascular Malformations pathology
- Abstract
Venous malformation (VM) is a prevalent congenital vascular anomaly characterized by abnormal blood vessel growth, leading to disfigurement and dysfunction. Sclerotherapy, a minimally invasive approach, has become a primary therapeutic modality for VM, but its efficacy is hampered by the rapid dilution and potential adverse effects. In this study, we introduced a series of cationic amphiphilic molecules, fatty alcohol esters (TA6, TA8, and TA9) of tranexamic acid (TA), which self-assembled into low-molecular-weight gels (LMWGs) in water. The TA9, in particular, is released slowly when hydrogel is injected into the vein locally. Then, it damages the venous wall by destroying cell membranes and precipitating proteins, causing inflammation and thrombosis, thickening of the venous wall, effectively inducing irreversible vein fibrosis. Additionally, TA9 can be rapidly degraded into TA in plasma to reduce toxicity caused by diffusion. Overall, this study suggests that the cationic amphiphilic molecule TA9 is a promising sclerosant for VM treatment, offering a novel, effective, and safe therapeutic option with potential for clinical translation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF